<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzUxOTgxNzg4NA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！ 投稿请发：442015666@qq.com 推广合作请联系：15057280775/15858667450</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 16 Jun 2021 10:08:20 +0800</pubDate><image><url>http://MzUxOTgxNzg4NA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzUxOTgxNzg4NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>药物无定形态的特点及其在制剂开发中的应用</title><link>https://mp.weixin.qq.com/s/KQMlKT4Ik1puRn1DOilbZw</link><description></description><content:encoded><![CDATA[药物无定形态的特点及其在制剂开发中的应用]]></content:encoded><pubDate>Wed, 16 Jun 2021 08:06:11 +0800</pubDate></item><item><title>【限免】60+嘉宾、800+企业加入，今夏你不容错过的新药研发盛会！</title><link>https://mp.weixin.qq.com/s/jg3o8agthJXfzYQVK-eZtA</link><description></description><content:encoded><![CDATA[【限免】60+嘉宾、800+企业加入，今夏你不容错过的新药研发盛会！]]></content:encoded><pubDate>Wed, 16 Jun 2021 08:06:11 +0800</pubDate></item><item><title>分析方法验证可接受标准深度剖析—线性篇</title><link>https://mp.weixin.qq.com/s/IVujcwkGWtlDcsj2Y7pp_Q</link><description></description><content:encoded><![CDATA[分析方法验证可接受标准深度剖析—线性篇]]></content:encoded><pubDate>Wed, 16 Jun 2021 08:06:11 +0800</pubDate></item><item><title>兰伯西从仿制药出海到梦碎美利坚，可带来怎样的启示</title><link>https://mp.weixin.qq.com/s/q7nj5pzHT7fv9SrjU3De2Q</link><description></description><content:encoded><![CDATA[兰伯西从仿制药出海到梦碎美利坚，可带来怎样的启示]]></content:encoded><pubDate>Mon, 14 Jun 2021 17:09:01 +0800</pubDate></item><item><title>液相故障排除指南(十三)：峰面积波动</title><link>https://mp.weixin.qq.com/s/ZJG8SK7pu3hKJsrn5VjfOw</link><description></description><content:encoded><![CDATA[液相故障排除指南(十三)：峰面积波动]]></content:encoded><pubDate>Mon, 14 Jun 2021 17:09:01 +0800</pubDate></item><item><title>分析方法验证可接受标准剖析—准确度与精密度篇</title><link>https://mp.weixin.qq.com/s/eoH1BZabK06ljBK9xaOyPA</link><description></description><content:encoded><![CDATA[分析方法验证可接受标准剖析—准确度与精密度篇]]></content:encoded><pubDate>Mon, 14 Jun 2021 17:09:01 +0800</pubDate></item><item><title>战狼传说：上市药企，销售团队Top100（附研发）</title><link>https://mp.weixin.qq.com/s/_ChyzxMv7ROAQ8-UeNNyQQ</link><description></description><content:encoded><![CDATA[战狼传说：上市药企，销售团队Top100（附研发）]]></content:encoded><pubDate>Sun, 13 Jun 2021 22:37:59 +0800</pubDate></item><item><title>【议程首发】中国AI新药合作大会</title><link>https://mp.weixin.qq.com/s/M5xu1MNPtri01qCP59zKFg</link><description></description><content:encoded><![CDATA[【议程首发】中国AI新药合作大会]]></content:encoded><pubDate>Sun, 13 Jun 2021 22:37:59 +0800</pubDate></item><item><title>5月份，FDA 批准上市新药汇总</title><link>https://mp.weixin.qq.com/s/Wu1lm6xxqsbYQPizXEiPvg</link><description></description><content:encoded><![CDATA[5月份，FDA 批准上市新药汇总]]></content:encoded><pubDate>Sun, 13 Jun 2021 22:37:59 +0800</pubDate></item><item><title>16个创新药申请临床，5款新药获批！荣昌生物、信达、贝达药业...  原创 不二  药融云  今天</title><link>https://mp.weixin.qq.com/s/zl4mKnPSqKN-Rco4ojiYwA</link><description></description><content:encoded><![CDATA[16个创新药申请临床，5款新药获批！荣昌生物、信达、贝达药业...  原创 不二  药融云  今天]]></content:encoded><pubDate>Sun, 13 Jun 2021 22:37:59 +0800</pubDate></item><item><title>机遇与挑战并存：中国高端制剂+改良新药峰会即将开幕</title><link>https://mp.weixin.qq.com/s/DHaYxMUJa_zUJaKmc6BaAw</link><description></description><content:encoded><![CDATA[机遇与挑战并存：中国高端制剂+改良新药峰会即将开幕]]></content:encoded><pubDate>Sun, 13 Jun 2021 22:37:59 +0800</pubDate></item><item><title>300多亿美元大市场，全球多肽药物8大重磅品种</title><link>https://mp.weixin.qq.com/s/fEVChH4H78rir75Ni0oURQ</link><description></description><content:encoded><![CDATA[300多亿美元大市场，全球多肽药物8大重磅品种]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧</title><link>https://mp.weixin.qq.com/s/JDN0aaoXA4KAuAcpRp2jMg</link><description></description><content:encoded><![CDATA[Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>新药研发质量体系建设与管理</title><link>https://mp.weixin.qq.com/s/gdT-5aeYTzBwkrGhfbevbg</link><description></description><content:encoded><![CDATA[新药研发质量体系建设与管理]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>首个国产ADC获批！荣昌生物管线中还有哪些重磅药？</title><link>https://mp.weixin.qq.com/s/MH2LNoRAW12PYh-xF6F6Gw</link><description></description><content:encoded><![CDATA[首个国产ADC获批！荣昌生物管线中还有哪些重磅药？]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>CML靶向药物评价指标，CDE征求《慢性髓性白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见</title><link>https://mp.weixin.qq.com/s/4ReErH8PMLReFO5PJXaZUg</link><description></description><content:encoded><![CDATA[CML靶向药物评价指标，CDE征求《慢性髓性白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>原料药中亚硝胺杂质的风险评估实操</title><link>https://mp.weixin.qq.com/s/RA9iDoY63zOqShInohnneQ</link><description></description><content:encoded><![CDATA[原料药中亚硝胺杂质的风险评估实操]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧</title><link>https://mp.weixin.qq.com/s/xO_GpPA3pKvKV8L3ibQEBw</link><description></description><content:encoded><![CDATA[Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>2021ASCO重磅登场，亚盛、百济、君实……，国内创新药企谁领风骚？</title><link>https://mp.weixin.qq.com/s/1qwT1cYAqFSbVZOqhNjJ8Q</link><description></description><content:encoded><![CDATA[2021ASCO重磅登场，亚盛、百济、君实……，国内创新药企谁领风骚？]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>已导致3名专家辞任！FDA争议AD新药​Aduhelm！</title><link>https://mp.weixin.qq.com/s/4DiF5eKRpK7H7rtT5zX7Dw</link><description></description><content:encoded><![CDATA[已导致3名专家辞任！FDA争议AD新药​Aduhelm！]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item></channel></rss>